Consumers will become ever-more mystified about what’s on a label
The most important lessons I’ve learned in pharmaceutical quality assurance during the last 40 years
Cost-cutting at Ford, compassionate-use drugs, and innovation stagnation
FDA recognizes that time is critical for seriously ill patients who do not have alternative therapies
All technology, all the time
What’s the difference?
Physical well-being and confidentiality depend on it
Public dockets will solicit feedback from patients, consumers, health providers, and state governments
In oncology drug development, government, regulatory medicine, and cancer advocacy
Self-climbing stairs, after-sales service, and can you be too concerned about quality?
FDA warning letters indicate the agency continues to be concerned about noncompliance
A plan for digital health devices
How to keep your profits from going flat
Medical device manufacturers want clarity
CDRH is walking the talk and expects device manufacturers to do the same
Zimmer Biomet uses PULSE and SmartQuality solutions for FDA compliance and continuous improvement
Five promising trends toward improving patient care
Making sense of vast streams of healthcare data
Small companies have a significant effect on U.S.-made pharmaceuticals
Valid advice for every manufacturing vertical, too